Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016
13 Décembre 2016 - 4:00PM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and C. difficile infection, will be announcing
its financial results for the third quarter and nine months ended
31 October 2016 on Thursday, 15 December 2016.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease DMD and the infectious disease Clostridium
difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
Summit
Therapeutics Glyn Edwards / Richard Pye
(UK office)Erik Ostrowski / Michelle Avery (US office) |
Tel: +44 (0)1235 443
951 +1 617 225 4455 |
|
|
Cairn Financial
Advisers LLP (Nominated Adviser)Liam Murray / Tony
Rawlinson |
Tel: +44 (0)20 7213
0880 |
|
|
N+1
Singer (Broker)Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496
3000 |
|
|
MacDougall
Biomedical Communications(US media contact)Chris Erdman /
Karen Sharma |
Tel: +1 781 235 3060
cerdman@macbiocom.com / ksharma@macbiocom.com |
|
|
Consilium
Strategic Communications (Financial public relations,
UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey
Neville |
Tel: +44 (0)20 3709
5700summit@consilium-comms.com |
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024